Clinical trial · Observational
Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will primarily compare the effectiveness of surgery and radiation for localized prostate cancer, the most common male cancer. It will focus on modern technologies and control for differences in patients and treatments that may affect both cancer-related and patient-reported outcomes (such as impotence and incontinence). By figuring out what treatments "work best, in which patients and in whose hands", it will help men with prostate cancer make better decisions regarding their care.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (7)
- label
- Open Radical Prostatectomy
- description
- 262
- label
- Robotic Radical Prostatectomy
- description
- 1303
- label
- Intensity-Modulated Radiotherapy
- description
- 638
- label
- Interstitial Brachytherapy
- description
- 171
- label
- combined EBRT and Brachytherapy
- description
- 143
- label
- Active Surveillance
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologic diagnosis of adenocarcinoma of the prostate * Clinically localized stage * PSA \<50ng/ml * age 18-79 Exclusion Criteria: * diagnosis of other malignancy (excluding squamous or basal cell carcinoma of the skin) within 3 years of diagnosis of prostate cancer * age 80 or greater * clinically locally advanced or metastatic disease * PSA equal to or greater than 50 ng/ml * pathologic diagnosis of prostate cancer greater than 6 months prior to baseline recruitment interview
References
Publications (0)
Data not yet available